Boston Scientific Corp said today the US District Court for the District of New Jersey ruled in its favour, finding all patents in a suit brought by Johnson & Johnson to be invalid.

Johnson & Johnson in the 2008 suit alleged that BostonScientific's Promus Everolimus-Eluting Coronary Stent System infringed two patents, known as the Morris patents, relating to the use of the drug on the stent.

Reuters